Meriofert Set (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

The human luteinising hormone and follicle‑stimulating hormone components bind to LH and FSH receptors on ovarian and testicular cells. This activates signaling pathways that increase steroid hormone production and promote the maturation of oocytes and sperm, supporting normal reproductive processes.

The dose of Meriofert Set is individualized and set by the prescribing clinician based on the patient’s hormonal profile, treatment goals and response to therapy. Specific dosing regimens are not provided here.

Meriofert Set is intended for use before conception to achieve pregnancy; it is not indicated for use during pregnancy. Safety data for breastfeeding are limited, and the product should be used with caution, following a physician’s assessment.

To order, submit an enquiry on the Meriofert Set product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Meriofert Set contains both LH and FSH activity in a single formulation, similar to combination products such as Menopur. Compared with separate LH and FSH preparations, it offers convenience of a single injection but may differ in specific dosing ratios, which clinicians consider when selecting therapy.

Meriofert Set should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product or shake the vial vigorously. Keep it in the original packaging until use to maintain stability.

The product is supplied as a sterile injectable solution and is administered by a trained healthcare professional via intramuscular or subcutaneous injection, typically into the thigh, buttock or abdominal wall, following aseptic technique.

Serious risks include severe ovarian hyperstimulation syndrome, which can cause abdominal pain, fluid accumulation and electrolyte imbalance, as well as the possibility of multiple gestation pregnancies and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these events.

Meriofert Set is contraindicated in individuals with known hypersensitivity to human LH or FSH, in patients with active ovarian cysts, uncontrolled thyroid disease, or those who are already pregnant. Caution is also advised for patients with severe cardiovascular disease or a history of thromboembolic events.